Universal Beteiligungs und Servicegesellschaft mbH Purchases New Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 408,700 shares of the biotechnology company's stock, valued at approximately $482,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.14% of Pacific Biosciences of California as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of PACB. Hsbc Holdings PLC lifted its holdings in shares of Pacific Biosciences of California by 10.3% during the 4th quarter. Hsbc Holdings PLC now owns 86,809 shares of the biotechnology company's stock worth $154,000 after acquiring an additional 8,106 shares during the period. AdvisorNet Financial Inc lifted its holdings in shares of Pacific Biosciences of California by 18.4% during the 1st quarter. AdvisorNet Financial Inc now owns 76,664 shares of the biotechnology company's stock worth $90,000 after acquiring an additional 11,895 shares during the period. Stifel Financial Corp lifted its holdings in shares of Pacific Biosciences of California by 33.2% during the 4th quarter. Stifel Financial Corp now owns 67,531 shares of the biotechnology company's stock worth $124,000 after acquiring an additional 16,843 shares during the period. Rhumbline Advisers lifted its stake in Pacific Biosciences of California by 4.8% in the 1st quarter. Rhumbline Advisers now owns 438,775 shares of the biotechnology company's stock valued at $518,000 after purchasing an additional 20,153 shares during the last quarter. Finally, ProShare Advisors LLC lifted its stake in Pacific Biosciences of California by 32.8% in the 4th quarter. ProShare Advisors LLC now owns 90,008 shares of the biotechnology company's stock valued at $165,000 after purchasing an additional 22,215 shares during the last quarter.

Analyst Ratings Changes

PACB has been the subject of several research reports. Canaccord Genuity Group reissued a "buy" rating and issued a $3.00 price objective on shares of Pacific Biosciences of California in a research note on Thursday, April 10th. Barclays dropped their price target on shares of Pacific Biosciences of California from $2.00 to $1.50 and set an "equal weight" rating for the company in a research note on Wednesday, June 25th. Stephens reaffirmed an "overweight" rating and set a $1.80 price target on shares of Pacific Biosciences of California in a research note on Thursday, May 15th. Finally, Piper Sandler dropped their price target on shares of Pacific Biosciences of California from $2.00 to $1.25 and set a "neutral" rating for the company in a research note on Thursday, May 15th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $2.06.

Pacific Biosciences of California Stock Performance

PACB traded down $0.12 during midday trading on Thursday, reaching $1.27. The company had a trading volume of 5,051,898 shares, compared to its average volume of 9,827,471. The company has a debt-to-equity ratio of 7.05, a quick ratio of 5.87 and a current ratio of 6.68. The stock has a market cap of $379.60 million, a PE ratio of -0.46 and a beta of 2.17. Pacific Biosciences of California, Inc. has a 12-month low of $0.85 and a 12-month high of $2.72. The business has a 50-day moving average price of $1.34 and a two-hundred day moving average price of $1.33.

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.04. Pacific Biosciences of California had a negative return on equity of 52.07% and a negative net margin of 430.93%. The firm had revenue of $37.15 million for the quarter, compared to analysts' expectations of $36.90 million. During the same quarter in the prior year, the firm earned ($0.26) EPS. On average, sell-side analysts expect that Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current fiscal year.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.